142 related articles for article (PubMed ID: 10792160)
1. Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression.
Zieger K; Wolf H; Olsen PR; Hojgaard K
BJU Int; 2000 May; 85(7):824-8. PubMed ID: 10792160
[TBL] [Abstract][Full Text] [Related]
2. Long term follow-up of superficial invasive bladder carcinoma with or without concomitant epithelial atypia--recurrence and progression.
Zieger K; Olsen PR; Wolf H; Højgaard K
Scand J Urol Nephrol; 2002 Feb; 36(1):52-9. PubMed ID: 12002359
[TBL] [Abstract][Full Text] [Related]
3. Does voided urine cytology have biological significance?
Tut VM; Hildreth AJ; Kumar M; Mellon JK
Br J Urol; 1998 Nov; 82(5):655-9. PubMed ID: 9839579
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival of patients with bladder tumours: the significance of risk factors.
Zieger K; Wolf H; Olsen PR; Højgaard K
Br J Urol; 1998 Nov; 82(5):667-72. PubMed ID: 9839581
[TBL] [Abstract][Full Text] [Related]
5. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
6. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years.
Larsson P; Wijkström H; Thorstenson A; Adolfsson J; Norming U; Wiklund P; Onelöv E; Steineck G
Scand J Urol Nephrol; 2003; 37(3):195-201. PubMed ID: 12775276
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group.
Mulders PF; Meyden AP; Doesburg WH; Oosterhof GO; Debruyne FM
Br J Urol; 1994 Apr; 73(4):403-8. PubMed ID: 8199828
[TBL] [Abstract][Full Text] [Related]
8. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
9. BTA test is superior to voided urine cytology in detecting malignant bladder tumours.
Heino A; Aaltomaa S; Ala-Opas M
Ann Chir Gynaecol; 1999; 88(4):304-7. PubMed ID: 10661829
[TBL] [Abstract][Full Text] [Related]
10. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success.
Lebret T; Gaudez F; Hervé JM; Barré P; Lugagne PM; Botto H
Eur Urol; 1998; 34(1):67-72. PubMed ID: 9676417
[TBL] [Abstract][Full Text] [Related]
11. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
12. The significance of tumour grade in predicting disease progression in stage Ta transitional cell carcinoma of the urinary bladder.
Chen SS; Chen KK; Lin AT; Chang YH; Wu HH; Hsu TH; Chang LS
Br J Urol; 1996 Aug; 78(2):209-12. PubMed ID: 8813915
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of stage Ta,T1 and Tis bladder tumors using Calmette-Guérin bacillus vaccine].
Bretheau D; Lechevallier E; Rossi D; Albert P; de Fromont M; Coulange C
Prog Urol; 1993; 3(4):608-17. PubMed ID: 8401621
[TBL] [Abstract][Full Text] [Related]
14. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
15. Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up.
Malmström PU; Busch C; Norlén BJ
Scand J Urol Nephrol; 1987; 21(3):185-95. PubMed ID: 3433019
[TBL] [Abstract][Full Text] [Related]
16. Bladder wash cytology at diagnosis of Ta-T1 bladder cancer is predictive for recurrence and progression.
Jancke G; Rosell J; Chebil G; Jahnson S
Urology; 2012 Sep; 80(3):625-31. PubMed ID: 22925239
[TBL] [Abstract][Full Text] [Related]
17. Significance of positive urine cytology on progression and cancer-specific mortality of non--muscle-invasive bladder cancer.
Koga F; Kobayashi S; Fujii Y; Ishioka J; Yokoyama M; Nakanishi Y; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
Clin Genitourin Cancer; 2014 Jun; 12(3):e87-93. PubMed ID: 24169493
[TBL] [Abstract][Full Text] [Related]
18. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
[TBL] [Abstract][Full Text] [Related]
19. Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression.
Kobayashi H; Kikuchi E; Mikami S; Maeda T; Tanaka N; Miyajima A; Nakagawa K; Oya M
BMC Urol; 2014 Jan; 14():5. PubMed ID: 24400640
[TBL] [Abstract][Full Text] [Related]
20. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study.
Denzinger S; Wieland WF; Otto W; Filbeck T; Knuechel R; Burger M
BJU Int; 2008 Mar; 101(5):566-9. PubMed ID: 17986289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
